Stock A243070 HUONS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Huons Co., Ltd. Stock

Equities

A243070

KR7243070000

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-04-24 pm EDT 		5-day change 1st Jan Change
34,250 KRW -0.44% Intraday chart for Huons Co., Ltd. +2.09% -10.81%
Mar. 27 PanGen Biotech Inc. announced that it has received KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd. CI
Mar. 20 Huons Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Financials

Sales 2024 * 620B 452M Sales 2025 * 681B 497M Capitalization 407B 296M
Net income 2024 * 53B 38.64M Net income 2025 * 60B 43.74M EV / Sales 2024 * 0.72 x
Net Debt 2024 * 41.3B 30.11M Net Debt 2025 * 42B 30.62M EV / Sales 2025 * 0.66 x
P/E ratio 2024 *
7.69 x
P/E ratio 2025 *
6.79 x
Employees 912
Yield 2024 *
1.75%
Yield 2025 *
1.75%
Free-Float 54.3%
More Fundamentals * Assessed data

Chart Huons Co., Ltd.

Dynamic Chart

Latest news about Huons Co., Ltd.

PanGen Biotech Inc. announced that it has received KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd. CI
Huons Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
PanGen Biotech Inc. announced that it expects to receive KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd. CI
GenEdit Inc. announced that it has received $24 million in funding from Korea Innovative Medicines Consortium, Dong-A ST Co., Ltd., Huons Co., Ltd. CI
Huons Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
South Korea's Huons to Export Anesthetics to Canada MT
GenEdit Inc. amended terms of the transaction CI
South Korean Stocks Turn Upbeat as China COVID-19 Lockdown Restrictions Ease; Huons Adds 1% MT
Huons to Invest $18.3 Million to Raise Production Capacity for Injectable Products at Jecheon Plant MT
GenEdit Inc. announced that it expects to receive $30 million in funding CI
Haemato : to Seek EU Approval for Botox Product MT
PanGen Biotech Inc. announced that it has received KRW 9.99998571 billion in funding from Huons Co., Ltd. and another investor CI
PanGen Biotech Inc. announced that it expects to receive KRW 9.99998571 billion in funding from Huons Co., Ltd., and another investor CI
Pharmcadd Co, Ltd announced that it has received $16 million in funding from a group of investors CI
Master Meditech Inc. announced that it has received KRW 8 billion in funding from Samho Green Investment, Inc., Paratus Investment Inc., Spring Camp, Huons Co., Ltd., Pharmbio Co., Ltd., INNOCENCE Co.Ltd CI
More news

Quotes and Performance

1 day-0.44%
1 week+2.09%
Current month-2.56%
1 month-2.42%
3 months-7.93%
6 months-13.29%
Current year-10.81%
More quotes

Highs and lows

1 week
33 100.00
Extreme 33100
34 650.00
1 month
32 850.00
Extreme 32850
36 250.00
Current year
32 850.00
Extreme 32850
40 350.00
1 year
28 900.00
Extreme 28900
49 500.00
3 years
27 600.00
Extreme 27600
78 636.36
5 years
25 330.58
Extreme 25330.5785
78 636.36
10 years
24 267.68
Extreme 24267.675
78 636.36
More quotes

Managers and Directors - Huons Co., Ltd.

Managers TitleAgeSince
Su-Young Song CEO
 Chief Executive Officer 61 -
Sang-Bae Yoon CEO
 Chief Executive Officer 54 -
Gi-An Eom PSD
 President 63 -
Members of the board TitleAgeSince
Sung-Tae Yoon CHM
 Chairman 59 92-06-30
Gi-An Eom PSD
 President 63 -
Duk-Ho Im BRD
 Director/Board Member 70 -
More insiders

Quotes

Date Price Change Volume
24-04-24 34,250 -0.44% 8 584
24-04-24 34,400 +0.29% 11,821
24-04-23 34,300 -0.29% 6,682
24-04-22 34,400 +1.93% 9,085
24-04-19 33,750 -0.30% 22,038

End-of-day quote Korea S.E., April 24, 2024

More quotes

Company Profile

Huons Co., Ltd. is a Korea-based company principally engaged in manufacture of general medicine and special medicine.
Sector
Pharmaceuticals
Calendar
2024-05-12 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for Huons Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
34,250 KRW
Average target price
54,000 KRW
Spread / Average Target
+57.66%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
HUONS CO., LTD. Stock Huons Co., Ltd.
-10.81% 297M
NOVO NORDISK A/S Stock Novo Nordisk A/S
+24.17% 562B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.12% 358B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.43% 322B
ABBVIE INC. Stock AbbVie Inc.
+7.72% 297B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.45% 219B
NOVARTIS AG Stock Novartis AG
+6.04% 199B
ROCHE HOLDING AG Stock Roche Holding AG
-10.51% 196B
PFIZER, INC. Stock Pfizer, Inc.
-11.76% 149B
AMGEN INC. Stock Amgen Inc.
-6.24% 146B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. A243070 Stock